Skip to main content
SpringerLink
Log in

Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The purpose of this study was to analyze the drug interactions of paclitaxel (PTX) with epirubicin (EPI), carboplatin (CBDCA), gemcitabine (GEM) and vinorelbine (VIN) in human breast cancer cells and compare the cytotoxic activity of each drug combination in primary breast cancer samples. These experiments were intended to identify the most active agents in combination with PTX, and to provide a preclinical rational for future clinical investigations in breast cancer. Multiple drug effect/combination index (CI) isobologram analysis was applied to combinations of PTX with either CBDCA, EPI, GEM or VIN in MCF-7, MDA-MB-231 and SK-BR-3 human breast cancer cell lines. Drug concentrations were limited to the ranges achievable in humans in vivo, and the drugs were applied simultaneously at fixed molar ratios for each drug combination. Interactions were assessed at multiple effect levels (IC10–IC90). Additionally, the cytotoxic activity of these combinations was assessed in tumor samples of 50 primary breast cancer patients, utilizing the ATP-tumorchemosensitivity assay (ATP-TCA). Drug interactions were shown to be strongly dose-related in the human breast cancer cell lines investigated. At clinically relevant concentrations, CBDCA/PTX demonstrated synergistic (MCF-7) or additive (MDA-MB-231, SK-BR-3) interactions, and EPI/PTX showed additive (SK-BR-3, MCF-7) and antagonistic (MDA-MB-231) interactions. GEM/PTX and VIN/PTX, however, demonstrated antagonism over multiple dose effect levels at clinically relevant drug concentrations in all three cell lines tested. At plasma peak concentrations, EPI/PTX, CBDCA/PTX, GEM/PTX and VIN/PTX achieved ≥90% tumor growth inhibition in 93, 86, 63 and 50%, respectively, of primary breast cancer samples investigated with the ATP-TCA. Cumulative dose-response plots of primary breast cancer tumor cells responding in vitro with ≥90% growth inhibition showed a strong dose dependence for both EPI/PTX and CBDCA/PTX. In conclusion, the current data indicate favorable drug interactions for CBDCA/PTX at clinically relevant drug concentrations in breast cancer cells, and demonstrate superior in vitro cytotoxicity of EPI/PTX and CBDCA/PTX compared to GEM/PTX and VIN/PTX in primary breast cancer cultures.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M: Paclitaxel versus doxorubic in as first-line single-agent chemotherapy for metastatic breast cancer: A European organization for research and treatment of cancer randomized study with cross-over. J Clin Oncol 18: 724-733, 2000

    Google Scholar 

  2. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, Klaassen U, Namer M, Bonneterre J, Fumoleau P, Winograd B: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14: 1858-1867, 1996

    Google Scholar 

  3. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688-2699, 1995

    Google Scholar 

  4. Sledge GW, Neuberg D, Ingle J, Martino S, Wood W: Phase III trial of doxorubicin (A) versus paclitaxel (T) versus doxorubicin +paclitaxel (A+T) as first-line therapy for metastatic breast cancer (MBC): An intergroup trial. Proc Am Soc Clin Oncol 16: 1a, abstr 2, 1997

    Google Scholar 

  5. Conte PF, Gennari A, Salvadori B, Pazzagli I, Bengala C, UO Oncologia Medica: Paclitaxel plus epirubic in in advanced breast cancer. Oncology 12(1, Suppl 1): 40-44, 1998

    Google Scholar 

  6. Lück HJ, Thomssen C, duBois A, Lisboa BW, Untch M, Kühnle H, Konecny G, Janicke F, Meerpohi HG, Lindner C, Hecker D, Diergarten K: Interim analysis of a phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer. Semin Oncol 23: 33-36, 1996

    Google Scholar 

  7. Martin M, Diaz-Rubio E, Casado A, Santabarbara P, Lopez Vega JM, Adrover E, Lenaz L: Carboplatin: An active drug in metastatic breast cancer. J Clin Oncol 10: 433-437, 1992

    Google Scholar 

  8. O'Brien ME, Talbot DC, Smith IE: Carboplat in in the treatment of advanced breast cancer: A phase II study using a pharmacokinetically guided dose schedule. J Clin Oncol 11: 2112-2117, 1993

    Google Scholar 

  9. Carmichael J, Walling J: Advanced breast cancer: Investigational role of gemcitabine. Eur J Cancer 33(Suppl 1):S27-S30, 1997

    Google Scholar 

  10. Canobbio L, Boccardo F, Pastorino G, Brema F, Martini C, Resasco M, Santi L: Phase-II study of Navelbine in advanced breast cancer. Semin Oncol 16(2 Suppl 4): 33-36, 1989

    Google Scholar 

  11. Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, Garcia-Giralt E, Keiling R, Namer M, Closon MT, Goudier MJ, Chollet P, Lecourt L, Montcuquet P: Phase II trial of weekly intravenous vinorelbine in firstline advanced breast cancer chemotherapy. J Clin Oncol 11: 1245-1252, 1993

    Google Scholar 

  12. Fountzilas G, Dimopoulos AM, Papadimitriou C, Kalogera-Fountzila A, Aravantinos G, Bafaloukos D, Athanaesiades A, Nicolaidos C, Keramopoulos A, Pavlidis N, Kosmidis P, Skarlos D: First-line chemotherapy with paclitaxel by three-hour infusion and carboplat in in advanced breast cancer (final report): A phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 9: 1031-1034, 1998

    Google Scholar 

  13. Colomer R, Llombart A, Lluch A, Ojeda B, Barnadas A, Caranana V, Fernandez Y, De Paz L, Guillem V, Alonso S: Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: Preliminary results of a phase II trial. Semin Oncol 27(1 Suppl 2): 20-24, 2000

    Google Scholar 

  14. Martin M, Lluch A, Casado A, Garciia Carbonero I, de Paz L, Esteban C, Alfonso R, Garcia-Conde J, Diaz-Rubio E: Paclitaxel plus vinorelbine: An active regimen in metastatic breast cancer patients with prior anthracycline exposure. Ann Oncol 11: 85-89, 2000

    Google Scholar 

  15. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984

    Google Scholar 

  16. Flick DA, Gifford GE: Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Methods 68(1-2): 167-175, 1984

    Google Scholar 

  17. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabblnavar F, Slamon D: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18: 2241-2251, 1999

    Google Scholar 

  18. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleiberman I, Caruso PA, Ricks SH, Untch M, Sartori C, Bruckner HW: Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: Clinical correlation for cisplatin resistance of ovarian cancer. Cancer Res 55: 5276-5282, 1995

    Google Scholar 

  19. Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR: Pharmacokinetics of cis-diammine-1, 1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res 44: 1693-1697, 1984

    Google Scholar 

  20. Speth PA, Linssen PC, Beex LV, Boezeman JB, Haanen C: Cellular and plasma pharmacokinetics of weekly 20-mg 4'-epi-adriamyc in bolus injection in patients with advanced breast carcinoma. Cancer Chemother Pharmacol 18: 78-82, 1986

    Google Scholar 

  21. Robert J: Clinical pharmacokinetics of epirubicin. Clin Pharmacokinetics 26: 428-438, 1994

    Google Scholar 

  22. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, Plunkett W: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9: 491-498, 1991

    Google Scholar 

  23. Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W: Gemcitabine in leukemia: A phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10: 406-413, 1992

    Google Scholar 

  24. Schilling T, Fiebig HF, Kerpel-Fronius S, Winterhalter B, Variol P, Tresca P, Heinrich B, Hanauske AR: Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patients. Invest New Drugs 14: 371-378, 1996

    Google Scholar 

  25. Jehl F, Quoix E, Leveque D, Pauli G, Breillout F, Krikorian A, Monteil H: Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography. Cancer Res 51: 2073-2076, 1991

    Google Scholar 

  26. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E: Phase I clinical and pharmacokinetic study of taxol. Cancer Res 47: 2486-2493, 1987

    Google Scholar 

  27. Huizing MT, Keung AC, Rosing H, van der Kuij V, ten Bokkel Huinink WW, Mandjes IM, Dubbelman AC, Pinedo HM, Beijnen JH: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11: 2127-2135, 1993

    Google Scholar 

  28. Von Hoff DD, Clark GM, Weiss GR, Marshall MH, Buchok JB, Knight WA III, LeMaietre CF: Use of in vitro dose response effects to select antineoplastics for high-dose or regional administration regimens. J Clin Oncol 4: 1827-1834, 1986

    Google Scholar 

  29. Hahn SM, Liebmann JE, Cook J, Fisher J, Goldspiel B, Venzon D, Mitchell JB, Kaufman D: Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro. Cancer 72: 2705-2711, 1993

    Google Scholar 

  30. Zoli W, Ricotti L, Barzanti F, Dal Susino M, Frassineti GL, Milandri C, Casadei Giunchi D, Amadori D: Scheduledependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. Int J Cancer 80: 413-416, 1999

    Google Scholar 

  31. Nguyen HN, Sevin BU, Averette HE, Perras J, Ramos R, Donato D, Oehiai K, Penalver M: Cell cycle perturbations of platinum derivatives on two ovarian cancer cell lines. Cancer Invest 11: 264-275, 1993

    Google Scholar 

  32. Tonkinson JL, Worzalla JF, Teng CH, Mendelsohn LG: Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 59: 3671-3676, 1999

    Google Scholar 

  33. Koechli OS, Sevin B-U, Perras JP, Chou TC, Angioli R, Steren A, Untch M, Averette HE: Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-cell viability assay. Breast Cancer Res Treat 28: 21-27, 1993

    Google Scholar 

  34. Akutsu M, Kano Y, Tsunoda S, Suzuki K, Yazawa Y, Miura Y: Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro. Eur J Cancer 31A: 2341-2346, 1995

    Google Scholar 

  35. Steel GG, Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity. Int J Radiat Oncol Biol Physics 5: 85-91, 1979

    Google Scholar 

  36. Liebmann JE, Fisher J, Teague D, Cook JA: Sequence dependence of paclitaxel (Taxol®) combined with cisplatin or alkylators in human cancer cells. Oncol Res 6: 25-31, 1994

    Google Scholar 

  37. Theodossiou C, Cook JA, Fisher J, Teague D, Liebmann JE, Russo A, Mitchell JB: Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines. Int J Oncol 12: 825-832, 1998

    Google Scholar 

  38. Carles G, Braguer D, Sabeur G, Briand C: The effect of combining antitubul in agents on differentiated and undifferentiated human colon cancer cells. Anti-Cancer Drugs 9: 209-221, 1998

    Google Scholar 

  39. Rowinsky EK, Cazenave LA, Donehower RC: Taxol: A novel investigational antimicrotubule agent. JNCI 82: 1247-1259, 1990

    Google Scholar 

  40. Budman DR: Vinorelbine (Navelbine): A third-generation vinca alkaloid. Cancer Invest 15: 475-490, 1997

    Google Scholar 

  41. Jordan MA, Toso RJ, Thrower D, Wilson L: Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90: 9552-9556, 1993

    Google Scholar 

  42. Derry WB, Wilson L, Jordan MA: Low potency of taxol at microtubule minus ends: Implications for its antimitotic and therapeutic mechanism. Cancer Res 58: 1177-1184, 1998

    Google Scholar 

  43. Toso RJ, Jordan MA, Farrell KW, Matsumoto B, Wilson L: Kinetic stabilization of microtubule dynamic instability in vitro by vinblastine. Biochemistry 32: 1285-1293, 1993

    Google Scholar 

  44. Kano Y, Atkutsu M, Suzuki K, Ando J, Tsunoda S: Scheduledependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro. Breast Cancer Res 56: 79-90, 1999

    Google Scholar 

  45. Jekunen AP, Christen RD, Shalinsky DR, Howell SB: Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 69: 299-306, 1994

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles School of Medicine, Los Angeles, CA, USA

    Gottfried Konecny, Dennis Slamon, Malgorzata Beryt & Mark Pegram

  2. Department of Obstetrics and Gynecology, Klinikum Grosshadern, Ludwig Maximillians Universität München, München, Germany

    Michael Untch, Steffen Kahlert, Margret Felber, Elena Langer, Sandra Lude & Hermann Hepp

Authors
  1. Gottfried Konecny
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Untch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dennis Slamon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Malgorzata Beryt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Steffen Kahlert
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Margret Felber
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Elena Langer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sandra Lude
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hermann Hepp
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mark Pegram
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Konecny, G., Untch, M., Slamon, D. et al. Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples. Breast Cancer Res Treat 67, 223–233 (2001). https://doi.org/10.1023/A:1017980411398

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1017980411398

Search

Navigation